Back to Blog
What to Expect

Is Compounded Tirzepatide Going Away?

•9 min read•By Aaliyah Mallard, PharmD

Is compounded tirzepatide going away? Not today. As of November 2026, the FDA's drug shortage database still lists Tirzepatide Injection as “Currently in Shortage,” and that shortage listing is what allows licensed 503A compounding pharmacies to prepare patient-specific copies of the medication. But “not today” is not the same as “never.” The legal basis for compounded tirzepatide is tied to that shortage status, so the honest answer is that it can change — and the change would follow a regulatory process you can watch, not a surprise announcement.

A small clear compounded tirzepatide vial beside a single dosing syringe resting on a folded linen cloth
Compounded tirzepatide is prepared by a licensed compounding pharmacy against a patient-specific prescription.

What “going away” actually means

Most of the confusion around this question comes from two very different things being described with the same words. One is the FDA moving to stop compounding of a molecule. The other is the official drug shortage ending. They are separate events, they run on separate timelines, and they have different consequences for you.

Start with what compounding actually is. Pharmacy compounding is a long-established, legal part of pharmacy practice: a licensed pharmacy prepares a medication to fit one specific patient's prescription. Under Section 503A of the Federal Food, Drug, and Cosmetic Act, a state-licensed pharmacy can compound for an individual patient when it holds a valid, patient-specific prescription from a licensed prescriber. That is the pathway most compounded GLP-1 prescriptions travel on.

There is a second pathway. A 503B outsourcing facility is registered with the FDA, operates under current good manufacturing practice requirements, and can produce larger quantities without individual patient prescriptions. Those facilities are inspected by the FDA on a risk-based schedule and have their own reporting obligations. A 503A pharmacy and a 503B facility are both legitimate; they are held to different rules and they are not interchangeable.

Then there is the part that applies to every compounded product: compounded drugs are not FDA-approved. The FDA does not evaluate a compounded copy for safety, effectiveness, or quality before it reaches a patient. That is not a loophole, it is a different regulatory track — and it shifts the quality burden onto the pharmacy doing the work.

So when someone says compounded tirzepatide is “going away,” they usually mean one of three things: that the FDA will prohibit compounding this molecule outright, that the shortage will be declared over and the 503A allowance will lapse, or that their own provider will stop selling it. Those are not the same problem, and only the first is what most people picture. For the record on where things stand right now, our article on whether compounded tirzepatide is still available covers the current status directly.

What would have to happen for compounding to stop

Compounded tirzepatide does not exist on a permanent license. It exists inside a set of conditions, and the most important one is the shortage listing.

The FDA drug shortage database is a public record of which drugs are in shortage and which have resolved. While tirzepatide injection is listed as in shortage, federal policy allows a licensed 503A pharmacy to compound a copy for a patient who has a valid prescription. If the FDA determines the shortage is resolved and removes the listing, that allowance is no longer available on the same basis, and compounding of a copy of that brand drug becomes far more restricted. That is the mechanism people are actually worried about.

The second condition is the 503A requirement itself: a valid prescription for a specific patient, issued after an actual clinical review. A pharmacy cannot mass-produce tirzepatide and sell it off a shelf. Someone has to evaluate you first.

The third is state law. Compounding rules, prescribing rules, and what a telehealth provider may do across state lines are set state by state. That is why the same product can be routine in one state and restricted in another, and why your address matters as much as the federal rules. The FDA's human drug compounding page lays out the federal framework.

What no one can give you is a date. Shortage resolutions are announced when they are announced, and states change rules on their own schedules. Anyone who tells you compounded tirzepatide ends on a specific month is guessing, even when they sound certain.

Where things stand now (November 2026)

Right now, the shortage listing is still in place. The FDA's database currently shows Tirzepatide Injection as “Currently in Shortage.” You do not have to take our word for it — the database is public and updated as the agency makes changes, so it is worth checking it yourself rather than relying on a headline.

On our side, compounded tirzepatide is $299 per month all-in, or $672 for a three-month supply, which works out to $224 per month. Shipping is free and typically arrives in two to three days, in temperature-controlled packaging. There is no insurance involved, no membership fee, and no subscription: you pay only if you are approved.

Two honest caveats belong in the same paragraph as the price. Pricing can change, and availability can change. Supply depends on what the licensed pharmacy can actually obtain, and availability varies by state. We would rather tell you that up front than have you find out at checkout. The current figures always live on the pricing page, and the service itself is described on the compounded tirzepatide page.

If the shortage ends, what changes for you

The practical answer is: not everything, and not all at once. Your prescriber's obligation to treat you appropriately does not disappear because a federal listing changed. What changes is which formulations are available to prescribe.

Three questions are worth asking before you start, not after: what is the plan if compounded tirzepatide stops being available, would a brand-name option such as Zepbound or Mounjaro fit my situation, and how would I be notified of a change? A provider who can answer those three has thought about the scenario. A provider who cannot is hoping you will not ask.

Be clear about the brand-name side too. Zepbound and Mounjaro contain the same active ingredient, tirzepatide, and they are FDA-approved products made by the manufacturer. They are also priced very differently from a compounded preparation, and insurance coverage for weight management varies widely. Moving to a brand product is a clinical and financial decision, not a straight swap.

The one thing not to do is stop abruptly in the middle of titration because you read that something might change. Stopping suddenly and restarting later at the same dose is exactly the pattern that produces a rough stretch of nausea and GI upset, and it is a clinical decision, not an administrative one. Talk to your prescriber first.

How to check your compounded tirzepatide is legitimate

Whatever happens with the shortage, the quality question does not go away. Most of the real risk in this category sits in the parts you cannot see on a checkout page, so here is what is worth confirming before you pay.

  • Which pharmacy, and what kind. Confirm it is a licensed 503A or 503B facility, and get the name. A provider that will not say is telling you something.
  • Sterile compounding standards. This is an injectable. Ask whether it is prepared in an ISO-classified cleanroom with environmental monitoring and sterility testing.
  • Third-party certificate of analysis. An independent lab result confirms the vial contains what the label says, at the stated concentration and purity.
  • Base tirzepatide, not a salt or analogue. Ask directly. “Tirzepatide acetate” or a “research chemical” version is a different product and is not intended for human use.
  • A licensed provider reviews your history. A prescription should follow an actual clinical review of your medications and conditions, not a short form that auto-approves everyone.
  • The real all-in cost. Add medication, consultation, and shipping together. A low headline price with separate fees can land higher than a flat one.
  • Cold-chain shipping. Ask how the medication stays cold in transit, especially in summer or if a package sits on a porch.
  • Support between refills. Who answers when you have a side effect at week three, and can your dose be adjusted without starting over?

The insight most people miss: the headline price matters less than who compounds it, who reviews your case, and what happens between refills. Two providers can charge the same $299 and be completely different products to live with. One has a pharmacist you can reach and a dose that gets adjusted; the other has a payment page.

How Halo-RX Meds handles availability

Halo-RX Meds is a woman-owned, pharmacist-led telehealth platform based in Georgia. Compounded tirzepatide is $299 per month, or $672 for a three-month supply, with free temperature-controlled shipping. No insurance is required, there is no subscription, and you pay only if you are approved.

The process is deliberately unglamorous. You start with a free screening — about five minutes, including ID verification — and a licensed prescriber, not an algorithm, reviews every submission. If you are approved, the medication is filled by a licensed compounding pharmacy and ships discreetly. Your care team handles dose questions, side-effect questions, injection questions, and refills through the portal rather than a phone tree. Support runs 7am to midnight ET, seven days a week, by text at (770) 370-7475. If you would rather talk it through first, there is a $49 fifteen-minute clarity call, and that fee is applied toward your first month if you move forward.

One limitation worth stating plainly: availability varies by state, and it depends on what the licensed pharmacy can supply. We cannot promise the medication will always be in stock, because that is not entirely within our control. What we can promise is that you will know where your order stands before you are charged.

Frequently Asked Questions

Is compounded tirzepatide going away in 2026?

Not as of November 2026. The FDA still lists Tirzepatide Injection as currently in shortage, and that listing is what allows licensed 503A pharmacies to prepare patient-specific copies. No one can give you a date for a change, because the timing depends on the FDA's shortage determination and on state rules.

Has the FDA banned compounded tirzepatide?

No. Compounding itself remains a legal part of pharmacy practice, and compounded tirzepatide is currently prepared under the 503A patient-specific prescription pathway while the shortage listing is in place. What is true is that compounded drugs are not FDA-approved, so the FDA does not review the product itself for safety or effectiveness before it reaches you.

What happens if my compounded tirzepatide is no longer available?

Talk to your prescriber before changing anything. They can tell you whether a brand-name option such as Zepbound or Mounjaro fits your situation, whether a different dose or formulation is appropriate, and how to transition safely. Do not stop abruptly mid-titration or restart later at a dose your body has not been on for a while without medical advice.

Is compounded tirzepatide the same as Zepbound or Mounjaro?

Same active ingredient, different regulatory status. Tirzepatide is the active ingredient in both brand-name products. A compounded preparation is made by a licensed pharmacy against your prescription and is not FDA-approved, while Zepbound and Mounjaro are FDA-approved products made by the manufacturer. Concentration and dosing units can differ between a compounded vial and a brand pen.

Can I still get compounded tirzepatide in my state?

It depends on where you live. Compounding and telehealth prescribing rules are set state by state, and Halo-RX availability varies by state as well. The reliable way to find out is to start the free screening or text the care team, so someone can confirm it for your state rather than guess.

Find out where you stand today

Start a free evaluation with Halo-RX Meds. A licensed prescriber reviews your history, and you pay only if you are approved.

Start Your Free Evaluation
Share:
AFFORDABLE COMPOUNDED OPTIONSSame active ingredient, a fraction of the cost

Save Up to 85% on Your GLP-1 Medication

Brand-name Ozempic and Wegovy can cost $900–$1,500 per month. Our compounded semaglutide and tirzepatide contain the same active ingredients as the brands, starting at just $199 — with free shipping and no insurance needed.

Brand Ozempic
$900+
per month
Insurance often required
Pharmacy pickup
Brand Wegovy
$1,300+
per month
Insurance often required
Pharmacy pickup
BEST VALUE
Halo Compounded
$199
Semaglutide / mo
$299
Tirzepatide / mo
No insurance needed
Free shipping
Same active ingredient2-3 day deliveryCare team supportNo hidden fees